Vitamin E supplementation has been widely studied in interventional trials in patients with cardiovascular disease, but the results have been disappointing. 1 These trials were planned on the assumption that vitamin E possesses antioxidant properties that may retard atherosclerosis. In the trial by Glynn et al, 2 vitamin E supplementation was given to healthy women on the assumption that vitamin E possessed antithrombotic properties that could prevent the occurrence of venous thromboembolism. During a follow-up of 10 years, the trial demonstrated that vitamin E supplementation (600 IU every other day) reduced the risk of venous thromboembolism, indicating that it may have an antithrombotic effect in vivo; however, the underlying mechanism of this effect was not clarified. The authors report that vitamin E interferes with vitamin K-dependent clotting factor activation 2 but fail to mention that, at concentrations achievable in the human circulation, vitamin E is also able to inhibit monocyte expression of tissue factor, a glycoprotein that converts factor X to Xa with a mechanism that may be dependent on its antioxidant properties. 3 It is therefore possible that, in vivo, vitamin E may act at different steps of the coagulation cascade. This issue is of possible clinical relevance when one takes into account potential vitamin E interference with oral anticoagulants or antithrombotic drugs such as anti-Xa or thrombin inhibitors.
Letter by Violi and Pignatelli Regarding Article, "Effects of Random Allocation to Vitamin E Supplementation on the Occurrence of Venous Thromboembolism: Report From the Women's Health Study"
To the Editor:
Vitamin E supplementation has been widely studied in interventional trials in patients with cardiovascular disease, but the results have been disappointing. 1 These trials were planned on the assumption that vitamin E possesses antioxidant properties that may retard atherosclerosis. In the trial by Glynn et al, 2 vitamin E supplementation was given to healthy women on the assumption that vitamin E possessed antithrombotic properties that could prevent the occurrence of venous thromboembolism. During a follow-up of 10 years, the trial demonstrated that vitamin E supplementation (600 IU every other day) reduced the risk of venous thromboembolism, indicating that it may have an antithrombotic effect in vivo; however, the underlying mechanism of this effect was not clarified. The authors report that vitamin E interferes with vitamin K-dependent clotting factor activation 2 but fail to mention that, at concentrations achievable in the human circulation, vitamin E is also able to inhibit monocyte expression of tissue factor, a glycoprotein that converts factor X to Xa with a mechanism that may be dependent on its antioxidant properties. 3 It is therefore possible that, in vivo, vitamin E may act at different steps of the coagulation cascade. This issue is of possible clinical relevance when one takes into account potential vitamin E interference with oral anticoagulants or antithrombotic drugs such as anti-Xa or thrombin inhibitors.
Another issue relates to the age of the population screened and its risk of venous thromboembolism. The trial included prevalently young women (Ϸ60% were Ͻ50 years of age, and only 10% were Ͼ65 years of age). As mentioned by the authors, the risk of venous thromboembolism increases with advancing age, and in fact thromboembolism occurred more often in women Ͼ55 years of age than in those Ͻ55 years of age. Analysis of these 2 subgroups shows that the reduction of venous thromboembolism was weak (about 10%) in women Ͻ55 years but more marked (Ͼ25%) in those aged Ͼ55 years. This finding is consistent with the subgroup analysis indicating that vitamin E would be more effective in women at higher risk, such as those with a previous history of venous thromboembolism or with coexistent genetic disorders. Despite these considerations of potentially different effects of vitamin E in young and old women, we suggest that (1) the inclusion of a relatively low number of patients Ͼ65 years of age may have erased major advantage in the vitamin E-treated group, and (2) women Ͻ55 years of age receive only marginal benefit from vitamin E supplementation. These arguments may have an impact on clinical practice mainly by helping to avoid the indiscriminate use of vitamin E supplementation and thus preventing potential harmful effects. 4
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